Sedar report: 1.running on fumes..2. Behind on quarterly payments due..60 days behind. 3. Need option 1 to happen during Q4 of 2020.

"Partnership discussions based on the results from the BETonMACE study, including the synergistic finding with new classes of anti-diabetic therapies, the pronounced effect on patients with CKD stages 3 or worse, the improvement in cognition in cognitively impaired patients and the observed effect on CHF are ongoing. Appropriate IP filings are also ongoing."

So, at the very least Don has four "on-going discussions" with Big Pharma;

Diabetic CVD
CKD
Dimentia
CHF

If he has competitors in each category that makes at least 8 on-going discussions.  Somethings got to give!  And in view of the MD&A's cash flow deficiency highlights, it had better happen really soon.  At least we won't have to wait long for news...of some sort or another.  Knock on wood.

GLTA